A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients (CORAL-I)

AbbVie logo

AbbVie

Status and phase

Completed
Phase 2

Conditions

Chronic Hepatitis C Infection

Treatments

Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir
Drug: ribavirin
Drug: ombitasvir/paritaprevir/ritonavir

Study type

Interventional

Funder types

Industry

Identifiers

NCT01782495
M12-999
2012-004792-39 (EudraCT Number)

Details and patient eligibility

About

The purpose of this study is to evaluate the safety and efficacy of ABT-450/r/ABT-267 with or without ABT-333 and with or without ribavirin (RBV) in adult liver or renal transplant recipients with hepatitis C virus (HCV) genotype 1 or 4 (GT1 or GT4) infection.

Enrollment

129 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male or female, at least 18 years of age at the time of screening.
  • Currently taking an immunosuppressant regimen based on either tacrolimus or cyclosporine. Corticosteroids such as prednisone or prednisolone are permitted as components of the immunosuppressant regimen providing the dose is not more than 10 mg/day.
  • Hepatitis C virus (HCV) interferon (IFN) therapy treatment-naïve or -experienced, either pre- or post-liver or renal transplant.
  • Screening HCV genotype testing indicating infection with genotype 1 or 4 (GT1 or GT4) only.

Exclusion criteria

  • Use of everolimus or sirolimus as part of the immunosuppressive regimen within 2 months of Screening Visit.
  • Use of any medications contraindicated for use with the study regimen as well as those that are contraindicated for use with either ritonavir or ribavirin within 2 weeks prior to study drugs administration or 10 half-lives (if known), whichever is longer.
  • Positive test result for Hepatitis B surface antigen (HBsAg) or anti-human immunodeficiency virus antibody (HIV Ab).
  • Documented history of post-transplant complications directly involving the hepatic or renal vasculature as appropriate to the organ transplanted, e.g., thrombosis of the portal vein, the hepatic artery and/or hepatic vein.
  • Clinically significant abnormalities, other than HCV infection, in a subject post-transplant based upon the medical history, physical examination, vital signs, laboratory profile and a 12-lead electrocardiogram (ECG) that make the subject an unsuitable candidate for this study in the opinion of the investigator.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

129 participants in 11 patient groups

Arm A
Experimental group
Description:
Liver transplant recipients with HCV genotype 1 infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 24 weeks.
Treatment:
Drug: ribavirin
Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir
Arm B
Experimental group
Description:
Liver transplant recipients with HCV genotype 1a or genotype 1b (dependent on prior treatment experience and response) infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 24 weeks.
Treatment:
Drug: ribavirin
Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir
Arm C
Experimental group
Description:
Liver transplant receipts with HCV genotype 1b infection who were treatment naïve or prior responders to interferon treatment without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) for 24 weeks.
Treatment:
Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir
Arm D
Experimental group
Description:
Liver transplant recipients with HCV genotype 1a infection with Child Pugh A cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (dosed 1,000 or 1,200 mg daily divided twice a day) for 24 weeks.
Treatment:
Drug: ribavirin
Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir
Arm E
Experimental group
Description:
Liver transplant recipients with HCV genotype 1b infection with Child Pugh A cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
Treatment:
Drug: ribavirin
Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir
Arm F
Experimental group
Description:
Liver transplant recipients with HCV genotype 1a infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
Treatment:
Drug: ribavirin
Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir
Arm G
Experimental group
Description:
Liver transplant recipients with HCV genotype 1b infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) for 12 weeks.
Treatment:
Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir
Arm H
Experimental group
Description:
Renal transplant recipients with HCV genotype 1a infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
Treatment:
Drug: ribavirin
Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir
Arm I
Experimental group
Description:
Renal transplant recipients with HCV genotype 1b infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) for 12 weeks.
Treatment:
Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir
Arm J
Experimental group
Description:
Liver transplant recipients with HCV genotype 4 infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
Treatment:
Drug: ribavirin
Drug: ombitasvir/paritaprevir/ritonavir
Arm K
Experimental group
Description:
Liver transplant recipients with HCV genotype 4 infection with Child Pugh A cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 24 weeks.
Treatment:
Drug: ribavirin
Drug: ombitasvir/paritaprevir/ritonavir

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems